Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) share price has underperformed over the past year, down nearly 64%. However, by the time the market opened on January 9, 2026, the stock had recorded a 7.19% share price gain over the previous five sessions. This recent stabilization in the stock is somewhat supported by a recent key pipeline update that refocused investor attention on the company's lead gene therapy program. On December 18, 2025, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced the initiation of a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration. The company is seeking accelerated approval of isaralgagene civaparvovec (ST-920) for adults with Fabry disease, with the submission allowing completed modules to be reviewed on an ongoing basis. It will potentially shorten the regulatory timeline ahead of a full filing expected in Q2 2026. The data from the registration STAAR study support the BLA, as it demonstrated ST-920's
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewswire
- How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewswire
SGMO
Earnings
- 11/6/25 - Miss
SGMO
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- SGMO's page on the SEC website